CALC: Continues Auxora Dosing
CalciMedica receives no FDA comments on its Phase 2 KOURAGE trial submission, allowing continued patient dosing with Auxora
CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora